We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

PURE Spa & Beauty

Status: Expired

Nov 30th 2018 - Feb 7th 2019

Aiming to improve the health and well-being of the UK by incorporating spa and beauty treatments into everyday life. PURE is a profitable business that currently runs 8 urban spas across Great Britain, as well as selling their own range of natural products and treatments for skincare to be used at home. Over 100k clients a year have used PURE's services, with 40% of appointments being booked via the company's website and mobile app. This has resulted in sales of £2.9m in 2017, with group revenue increasing by more than 21% in the year-to-date.

Investments will be used to open in more locations, develop more products and expand the PURE Beauty Zone marketplace for independent health and beauty businesses to sell their products in PURE's spas and on their website.

read more read less
Log in to view amount pledged

    Log in to view target

    £10,000,000
    pre-money valuation

    1.48%
    equity available

    128
    investors

    £568
    pledge per investor

    06673755
    company number

    Dissolved
    company status

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    12 May 24 Crowdcube £72,650 / 48%

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £10,000,000
    pre-money valuation

    1.48%
    equity available

    128
    investors

    £568
    pledge per investor

    06673755
    company number

    Dissolved
    company status

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    12 May 24 Crowdcube £72,650 / 48%
    Officers
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph